Complaint Counsel's Post Trial Brief - Federal Trade Commission

More documents

Recommendations

Info

CX44 Danel Chapter One Monthy Gross Sales (marked as Exhbit 9 at Respondent James D. Feijo's Januar 13, 2009 deposition) CX45 Email and Attachments from Jay Harson to Patrcia Feijo (marked as Exhbit 10 at Respondent James D. Feijo's Januar 13, 2009 deposition) CX46 Universal Nutrtion invoices (marked as Exhbit HOJ Tr. 239, 259 20 at Claudia Petra Bauhoffer-Kiey's Januar 15, 2009 deposition) CX47 Letter from Claudia Petra Bauhoffer-Kiey to Respondent James D. Feijo (marked as Exhbit 21 at Claudia Petra Bauhoffer-Kiey's Januar 15, 2009 deposition) CX48 Respondents' Amercan Express Gold Card HOJ Tr. 151-60 Records (FTC-DCO 2963 - 3338) CX49 Respondents' Citizens Ban Records HOJ Tr. 161-68,228-32 (FTC-DCO 3339 - 3839) CX50 Respondents' Corporate Records from the Rhode HOJ Tr. 101-09, 118, Island Offce or the Secretar of State 120-21, 123-24, 173-79, (FTC-DCO 3840 - 3872) 194-97 CX51 Copy of the Declaration of Independence HOJ Tr. 98-99 CX52 Exper Witness Report of Denis R. Miler, M.D. COMPLAIT COUNSEL'S WITNESS INDEX Complaint Counsel called the following witnesses in ths proceeding: 1. Michael Marino Investigator, Federal Trade Commssion One Bowling Green, Suite 318 New York, NY 10004 Transcript pages at which the witness's testimony appears: HOJ Tr. 51-68. 6
2. James Feijo Owner and President, Danel Chapter One 1028 East Main Road Portsmouth, RI 02871-0223 Transcript pages at which the witness's testimony appears: HOJ Tr. 69-239; Tr. 415-64. 3. Denis R. Miler, M.D. 36 East Lake Road Tuxedo Park, NY 10987 Transcript pages at which the witness's testimony appears: Tr. 28-229. Dated: May 28, 2009 Respectfully submitted, ~~ Yl~ Leon d L. Gordon (212) 607-2801 Theodore Zang, Jr. (212) 607-2816 Carole A. Paynter (212) 607-2813 David W. Dulabon (212) 607-2814 Elizabeth K. Nach (202) 326-2611 Wiliam H. Efron (212) 607-2827 Federal Trade Commission Alexander Hamlton U.S. Custom House One Bowling Green, Suite 318 New York, NY 10004 7
Page 1 and 2:
UNITED STATES OF AMERICA BEFORE THE
Page 3 and 4:
TABt
Page 5 and 6:
TABLE OF CONTENTS i. Complaint Coun
Page 7 and 8:
14. "The priciples of BioMolecular
Page 9 and 10:
38. Respondents have generated appr
Page 11 and 12:
Respondent DCO "is the ONLY nutrtio
Page 13 and 14:
priced with most other brands but w
Page 15 and 16:
Florida, which Respondent DCO owns.
Page 17 and 18:
C. Respondents Claim That Their Pro
Page 19 and 20:
and the tuor behind my hear has shr
Page 21 and 22:
BioMixx TM. . . GDU Caps TM. . . (d
Page 23 and 24:
east examnation by mamography. On 1
Page 25 and 26:
185. The DCO radio program and the
Page 27 and 28:
211. Universal Nutrtion has not con
Page 29 and 30:
233. Nevertheless, Dr. Miler cautio
Page 31 and 32:
262. When enterng in the MA an acti
Page 33 and 34:
292. Duke made no effort to see whe
Page 35 and 36:
nutrtional supplements and botancal
Page 37 and 38:
352. LaMont acknowledged that there
Page 39 and 40:
383. Dews never has heard of James
Page 41 and 42:
412. Dews is not famliar with any s
Page 43 and 44:
442. There are no indications in Du
Page 45 and 46:
472. LaMont does not know whether B
Page 47 and 48:
114 F.T.C. at 322; Thompson Medical
Page 49 and 50:
it was not blinded or placebo-contr
Page 51 and 52: Tech., Inc., 128 F.T.C. 299 (1999)
Page 53 and 54: In the Matter of ) ) DANIEL CHAER O
Page 55 and 56: a. The Adverisements in Question Ma
Page 57 and 58: In the Matter of ) ) DANIEL CHAER O
Page 59 and 60: CCPF ~ 16-18. In 2002, James Feijo
Page 61 and 62: the ter "BioMolecular Nutrtion" to
Page 63 and 64: 1. Claims That the DCO Products Are
Page 65 and 66: above the brain stem. . . has compl
Page 67 and 68: direct statements. Id. at 318 and 3
Page 69 and 70: 12-12A; CCPF ~ 35. Respondents make
Page 71 and 72: c. Respondents Represented that GDU
Page 73 and 74: CCPF ~ 140 (emphasis in bold added)
Page 75 and 76: consistent with the FTC's approach.
Page 77 and 78: not cure the fact that the claims a
Page 79 and 80: fudamental requirements for scienti
Page 81 and 82: competent and reliable scientific e
Page 83 and 84: humans with cancer. CCPF ~ 228. il.
Page 85 and 86: lines of evidence." CCPF ~ 280. LaM
Page 87 and 88: effectiveness ofGDU, BioMixx, Bio*S
Page 89 and 90: adverisements and promotional mater
Page 91 and 92: canot, however, make deceptive stat
Page 93 and 94: dosages ofthe DCO Products. CCPF ~~
Page 95 and 96: VI. CONCLUSION The evidence at tral
Page 97 and 98: In the Matter of DANIEL CHAPTER ONE
Page 99 and 100: CX 14 Attachment C to Administrativ
Page 101: CX33 Emails from DCO relating to FT
show all

Complaint Counsel's Post Trial Brief - Federal Trade Commission

Create successful ePaper yourself

Delete template?

Save as template?